Magenta Therapeutics, Inc. (24)

Browse by Contract Category

Contracts

Amended and Restated Employment Agreement by and between the Registrant and David Nichols, effective May 2, 2022 (Filed With SEC on May 2, 2022)
Master Services Agreement, dated as of May 22, 2019, by and between the Registrant and Heidelberg Pharma Research GmbH (Filed With SEC on March 8, 2022)
Securities Purchase Agreement, dated as of May 12, 2021, among Magenta Therapeutics, Inc. and each purchaser party thereto (Filed With SEC on May 12, 2021)
Second Amendment to Sublease Agreement, dated as of August 19, 2020, by and between the Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on March 3, 2021)
Description of Securities of the Registrant (Filed With SEC on March 3, 2020)
Amendment, effective as of July 4, 2019, pursuant to the Exclusive Research, Development Option and License Agreement by and between the Registrant and Heidelberg Pharma Research... (Filed With SEC on November 13, 2019)
Amended and Restated Employment Agreement by and between the Registrant and Thomas Beetham, effective May 2, 2022 (Filed With SEC on May 2, 2022)
Amended and Restated Employment Agreement by and between the Registrant and Stephen Mahoney, effective March 3, 2022 (Filed With SEC on March 8, 2022)
Amended and Restated Employment Agreement by and between the Registrant and Jason Gardner, effective March 3, 2022 (Filed With SEC on March 8, 2022)
Employment Agreement by and between the Registrant and Stephen F. Mahoney, effective November 9, 2020 (Filed With SEC on May 6, 2021)
Amendment #2 to Project Rider #1, effective as of November 13, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a... (Filed With SEC on March 3, 2021)
Amendment #1 to Collaboration Agreement, effective as of December 31, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program... (Filed With SEC on March 3, 2021)
Amendment #3 to Project Rider #1, effective as of December 16, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a... (Filed With SEC on March 3, 2021)
First Amendment to Employment Agreement, executed as of October 14, 2020, by and between the Registrant and John C. Davis, Jr., M.D (Filed With SEC on November 5, 2020)
Underwriting Agreement, dated as of June 24, 2020, by and among Magenta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Cowen and Company, LLC, as representatives of the... (Filed With SEC on June 30, 2020)
Underwriting Agreement, dated as of June 24, 2020, by and among Magenta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Cowen and Company, LLC, as representatives of the... (Filed With SEC on June 30, 2020)
Amendment #1 to Project Rider #3, effective as of August 26, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be... (Filed With SEC on November 13, 2019)
2019 Employee Stock Purchase Plan (Filed With SEC on June 11, 2019)
First Amendment to Sublease by and between Novartis Institutes for BioMedical Research, Inc. and the Registrant, dated as of December 13, 2018 (Filed With SEC on April 29, 2019)
Letter Agreement, effective as of February 28, 2019, by and between the Registrant and Heidelberg Pharma Research GmbH relating to the Exclusive Research, Development Option and... (Filed With SEC on April 29, 2019)
Form of Underwriting Agreement (Filed With SEC on April 29, 2019)
Project Rider #3, effective as of September 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10,... (Filed With SEC on March 19, 2019)
Amendment #1 to Project Rider #1, effective as of December 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as... (Filed With SEC on March 19, 2019)
Project Rider #2, effective as of June 26, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10, 2017 (Filed With SEC on March 19, 2019)